Walk into any smoke shop or gas station with a kratom display and you’ll see a half-dozen formats at wildly different price points, sold under names and potency labels that aren’t easy to parse. Patients routinely arrive at intake unsure what they’ve actually been taking. This article is the plain-language guide to the product categories so you can describe your use accurately to a provider — and, more importantly, understand why the escalation pattern that is so common in kratom use is a pharmacologic feature of the product landscape, not a personal failing.
Start With the Basics: Mitragynine and 7-OH
Kratom (Mitragyna speciosa) leaves contain over 50 alkaloids, but two matter clinically: mitragynine (typically 1–2% of dry leaf weight) and 7-hydroxymitragynine (7-OH) (typically under 0.05% of dry leaf weight). Both activate the mu-opioid receptor. 7-OH is the more potent agonist of the two.
Everything below is a different way of delivering different proportions and concentrations of these alkaloids.
Category 1: Leaf Powder
Dried, ground kratom leaf. Green/red/white “veins” (the branding refers to different drying processes, though alkaloid differences between veins are modest). Typical serving is 2–5 grams of powder; higher doses climb from there.
- Alkaloid profile: Full spectrum. Roughly 1–2% mitragynine by weight, trace 7-OH.
- Onset: 30–60 minutes.
- Duration: 3–5 hours typically.
- Addiction profile: Dependence develops with regular daily use. Typically milder withdrawal than concentrated products.
- Legal status in Tennessee: Currently legal for adults 21+ under TN Code § 39-17-452.
Leaf powder is the “traditional” form. Most of the clinical literature on kratom use and dependence is built on leaf-powder users. If a provider asks what kind of kratom you’re using and you’re using leaf powder, “leaf powder” is the right answer — it sets clinical expectations appropriately.
Category 2: Capsules
Leaf powder packed into gelatin capsules for easier dosing. Each capsule is typically 500 mg–1 g of leaf powder.
Pharmacologically: identical to leaf powder. Same onset, duration, alkaloid profile. The capsule is just a delivery convenience. The upsides are dose consistency (you know how much is in each capsule) and not having to taste the powder.
Category 3: “Extract” Products (1x/5x/10x/20x)
This is where the product landscape starts getting confusing. An “extract” is leaf powder processed to concentrate the alkaloid content. The “5x” or “10x” label implies that a gram of extract has 5 or 10 times the alkaloid content of a gram of leaf — but these labels are not standardized across manufacturers and testing inconsistencies are common.
- Alkaloid profile: Higher mitragynine per gram. 7-OH content can be elevated depending on the extraction method.
- Onset: Similar to leaf but with steeper peak effects at common doses.
- Addiction profile: Harder withdrawal than leaf. Faster tolerance climb.
- Legal status: Generally legal in Tennessee if sold within the parameters of TN Code § 39-17-452, though some processed products fall into the already-restricted category depending on chemical modification.
Escalation from leaf powder to 5x/10x extracts is one of the most common patterns we see at intake. Patients describe it as “the leaf stopped working” — the leaf didn’t stop working, their tolerance climbed and they needed more concentrated input to get the same effect.
Category 4: Tinctures and Liquid Shots
Alcohol- or glycerin-based extracts, often sold in small bottles for sublingual or mixed use. Alkaloid content varies widely; some shots market a specific mitragynine content per serving.
The key difference from leaf: faster onset and more predictable blood level spikes. Sublingual or liquid delivery produces a steeper up-slope than swallowed powder, which can make the product feel stronger at the same total alkaloid dose.
Category 5: Concentrated 7-OH Products
This is the category the FDA specifically flagged for Schedule I recommendation in July 2025. Tablets, gummies, lozenges, and shots containing isolated or heavily concentrated 7-hydroxymitragynine — the more potent of the two main kratom alkaloids.
- Alkaloid profile: Primarily 7-OH, often at milligram or multi-milligram doses per serving — hundreds of times higher than what leaf delivers per gram.
- Onset: Fast, particularly for sublingual or chewable products.
- Duration: Often shorter than leaf — 2–4 hours — which drives more frequent dosing.
- Addiction profile: The hardest to come off. Deeper receptor adaptation, faster-onset withdrawal, more intense symptoms. Relapse rates on self-taper are substantially higher than for leaf.
- Legal status: State-level depends on specific product; federally under active FDA/DEA review with Schedule I recommendation from July 2025. See our Is Kratom Legal in Tennessee article for the current picture.
If you’ve been using concentrated 7-OH products, the category matters for treatment planning. Induction timing, dose, and expected withdrawal profile are all different from leaf-powder patients.
Why This Product Landscape Drives Escalation
The typical arc we hear at intake:
- Started with leaf powder once a day for energy or mood.
- Moved to capsules for convenience; dose increased.
- Tried a 5x extract because leaf felt weaker.
- Switched to a tincture for faster onset.
- Noticed 7-OH tablets at the gas station; tried one.
- Realized within days or weeks that the tablets were the only thing that worked the way leaf used to — and started dosing them 3–5 times a day.
This isn’t a personal failing. It’s a pharmacologic inevitability in a product market where stronger options are always one shelf over, and where tolerance climbs continuously under regular use. The most reliable predictor of arriving at concentrated 7-OH dependence isn’t anything about the person — it’s the number of months of continuous kratom use combined with easy access to progressively stronger products.
What to Tell Your Provider at Intake
When you call 423-498-2000 to schedule, or when you arrive for your first visit, give the most specific version of your use pattern you can. Helpful details:
- Product category (leaf powder, extract, tincture, tablet, gummy, etc.)
- Brand or source if you remember
- Typical daily total (grams of leaf, number of tablets, ml of tincture, whatever fits)
- Frequency (once a day, three times, every two hours, etc.)
- Duration of use (weeks, months, years)
- Recent escalations — any product switches or dose increases in the last month or two
- Last use — when was your most recent dose and what was it
Specifics matter because induction timing depends on which product and when you last used. A patient on leaf powder has a different induction window than a patient on concentrated 7-OH.
What None of This Changes
Regardless of category, the pharmacologic mechanism is the same: mu-opioid receptor activation. And the treatment mechanism is the same: buprenorphine-based MAT fills the same receptors and stabilizes the system. The protocol adjusts for category (timing, dose, expected withdrawal profile), but the core approach is consistent.
If you’re dependent, the right next step is a phone call, not a self-directed product switch.